Functional RNAi and CRISPR Screening and Drug Target & Biomarker Discovery
Cellecta Inc., a functional genomics solutions provider, focuses primarily on developing and implementing flexible and scalable broad-based screening and analysis approaches for drug target and biomarker discovery. Our high-throughput functional genetic screening portfolio includes:
- shRNA and CRISPR screening services
- custom and off-the-shelf pooled libraries
- knockout and knockdown cell lines
that facilitate genome-wide functional screening and the identification and validation of genes involved in critical biological and disease pathways.
With DriverMap™ Targeted Gene Expression Profiling Service, Cellecta offers a quantitative, multiplexed approach that allows simultaneous profiling of all human protein-coding genes in one reaction, thereby providing a reliable, accurate transcriptome profile with ultra-high sensitivity.
Learn more about Cellecta >
Upcoming Events
CHI World Preclinical Congress, Westin Copley Place, Boston, MA, June 18-21, 2018. Come see us at Booth # 301.
CRISPR 2018 Meeting, Hotel Radisson Blue Lietuva, Vilnius, Lithuania, June 20-22, 2018.
FASEB Genome Engineering: Cutting-Edge Research and Applications, Hilton Metropole Florence, Florence, Italy, June 24-29, 2018.
Sixth JCA-AACR Special Conference on Lung Cancer Research, Kyoto Tokyu Hotel, Kyoto, Japan, July 10-12,2018.
DriverMap™ Targeted Expression Profiling
With DriverMap, Cellecta offers a novel, comprehensive end-to-end service portfolio for identifying differential gene expression, mapping of clinically actionable mutations in RNA, detecting cellular composition, and profiling immunotherapy targets.
Pooled Lentiviral shRNA and CRISPR Libraries
Cellecta, partnered with RPCI, FHCRC, and TSRI has created one of the most effective and published pooled shRNA library platforms available. We now also offer pooled premade and custom CRISPR libraries.
Complete Loss-of-Function RNAi and CRISPR Screening Services
We’ll perform any or all steps, from RNAi and CRISPR screening to NGS to data analysis. Cellecta specializes in negative screens (i.e. viability or drop-out) to identify cancer drug targets.
